An open-label study to evaluate correct use and ease of use of the ELLIPTA DPI in pediatric subjects with asthma

Trial Identifier: 206924
Sponsor: GlaxoSmithKline
Start Date: June 2018
Primary Completion Date: December 2018
Study Completion Date: December 2018
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, Ontario Brampton, Ontario, Canada, L6T 0G1
Canada, Ontario Burlington, Ontario, Canada, L7N 3V2
Canada, Ontario London, Ontario, Canada, N6A 1V2
Canada, Ontario Windsor, Ontario, Canada, N8X 2G1
United States, Arkansas Little Rock, Arkansas, United States, 72205
United States, California Huntington Beach, California, United States, 92648
United States, California Napa, California, United States, 94558
United States, Florida Aventura, Florida, United States, 33180
United States, Florida Miami, Florida, United States, 33173
United States, Florida Plantation, Florida, United States, 33324
United States, Kentucky Owensboro, Kentucky, United States, 42301
United States, Minnesota Minneapolis, Minnesota, United States, 55402
United States, Minnesota Plymouth, Minnesota, United States, 55441
United States, Missouri Columbia, Missouri, United States, 65203
United States, Missouri Rolla, Missouri, United States, 65401
United States, North Carolina Asheville, North Carolina, United States, 28801
United States, South Carolina Summerville, South Carolina, United States, 29485
United States, Texas Austin, Texas, United States, 78759-8950
United States, Texas Waco, Texas, United States, 76712